What was also interesting, is that Joel mentioned whoever is...

What was also interesting, is that Joel mentioned whoever is first to market via the FDA has 7 years of exclusivity, which is massive. He noted that they have some complex metric/system that they use that indicates that they are currently are Infront of any competitors to get the FDA approval. He also mentioned for OSA that they don't even needed to generate the same efficacy data as the phase 2, the biggest priority from the FDA perspective is safety, which is why it's 52 weeks